Common InfectionsQUERI VASTNCT07877662
VA Quality Enhancement Research Initiative (QUERI) CARRIAGE VAST
A study testing Videoconference Antimicrobial Stewardship Team in people with Common Infections and Urinary Tract Infections, run by VA Office of Research and Development at 1 site in United States.
Trial summary
Antimicrobial-resistant and healthcare-associated pathogens are a global health threat. The goals of antimicrobial stewardship are to minimize unnecessary and inappropriate antimicrobial use as a means to combat antimicrobial resistance. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Common Infections, Urinary Tract Infections, Respiratory Tract Infections
- What is being tested?
- Videoconference Antimicrobial Stewardship Team
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Nov 2025to 30 Sep 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- -VA medical centers without local ID expertise that pair with an ID-expert from another VA medical center
Who cannot join
- -none
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Edward Hines Jr. VA Hospital, Hines, IL
Hines, Illinois, 60141-3030
About this study
Official title: Implement and Assess the Impact of a Multidisciplinary Videoconference Antimicrobial Stewardship Team (VAST) in Rural VAMCs Using Telehealth on Antimicrobial Prescribing (QUE 25-023)
Antimicrobial-resistant and healthcare-associated pathogens are a global health threat. The goals of antimicrobial stewardship are to minimize unnecessary and inappropriate antimicrobial use as a means to combat antimicrobial resistance. The interdisciplinary Videoconference Antimicrobial Stewardship Team (VAST) was initially developed and tested as a telehealth teleconferencing training and mentoring program in 2 rural pilot sites, then was extended to 9 rural sites, using telehealth to connect clinicians at a rural VAMC to a geographically distant infectious disease expert. Qualitative interviews showed that participants valued VAST and it improved patient care. This project will expand the VAST to other VAMCs and assess the VASTs' impact on antimicrobial prescribing. This work will directly increase access to antimicrobial stewardship consultation at rural VA facilities, which are often underserved by infectious disease expertise.
Read the detailed description
Background: Antimicrobial resistance (AMR) is a current pandemic. Access to ID physicians and pharmacists in VHA is limited and many VHA healthcare systems do not have an ID specialist. This gap in expertise is detrimental, as the presence of ID trained physicians and pharmacists in acute care is associated with improved antimicrobial utilization. Telehealth can facilitate antimicrobial stewardship in VA facilities underserved by ID expertise. The interdisciplinary Videoconference Antimicrobial Stewardship Team (VAST)consists of weekly meetings between an interdisciplinary team at a rural VAMC with an off-site ID trained physician and/or pharmacist who meet by videoconference. At each session, participants discuss patients receiving antibiotics or who may potentially receive antibiotics. Team members enter the VAST's recommendations into the electronic medical record (EMR) at the rural VAMC. The ID physicians capture their clinical effort by completing interfacility consults placed through the EMR. The aims of this hybrid effectiveness trial are to assess the implementation of VAST and antibiotic utilization outcomes.
Aim 1: Implement and evaluate the implementation of VAST, using an implementation playbook with external facilitation and tailoring. VAST will be implemented over 15 months, plus sustainability follow-up in 6 rural VAMCs using key implementation strategies of external facilitation provided by CARRIAGE, tailoring and adaptation of VAST, and use of an implementation playbook. Process maps (which informed the playbook) from the previous VAST expansion captured VAST experiences at each site and illuminated successful implementation processes, showing that tailoring and adapting the VAST program based on site-specific needs, individual clinical processes, and patient care needs was crucial to its success and sustainability. The playbook details the general process for setting up an e-consult VAST clinic and scheduling and conducting VAST sessions. Site-specific tailoring, adaptation, and facilitation of VAST will occur based on playbook information. CARRIAGE members will hold initial facilitation calls weekly with VASTs, with ad hoc support available as well. CARRIAGE will facilitate an initial kick off meeting via Teams for each VAST to encourage team building and expectations for the ensuing sessions.
Aim 2: Assess the impact of VAST on antimicrobial use and the care of Veterans with suspected and confirmed infections. Using a quasi-experimental design, the investigators will assess outcomes for new rural sites implementing VAST and for the current rural sites currently using VAST to assess sustainability. For each site, the investigators will calculate these statistics monthly for the 12 months prior to and 15 months following the first VAST session (allowing for a 3-month wash-in period), and up to 24 months to assess sustainability. The investigators will include a control group of rural sites not utilizing VAST (matched). Antibiotic use metrics including rates of total and broad-spectrum anti-biotic use, antibiotic starts, and length of antibiotic therapy will be evaluated. The primary outcome is days of antibiotic therapy per 1000 days of care (DOT/1000 DOC) to measure the overall rate of antibiotic use; key secondary outcomes include rate of broad-spectrum antibiotics, defined as agents with an Antibiotic Spectrum Index score of ≥ 8;72 rate of antibiotic starts, calculated as the number of new starts per 1000 DOC; and length of antibiotic therapy in days. Other outcomes may be evaluated including management of resistant infections including treatment selection. The investigators will use VA CDW/Millennium to obtain antimicrobial prescribing, diagnosis, comorbidity, microbiologic, laboratory, and demographic data.
- Being tested
- Videoconference Antimicrobial Stewardship Team
- Keywords
- Antimicrobial stewardship, Telemedicine, Rural health
- Medical subject headings
- Urinary Tract Infections, Respiratory Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Videoconference Antimicrobial Stewardship TeamOther
Also called VAST
Implementation of VAST in hybrid effectiveness trial. Sites that implement VAST will have outcomes measured before and after implementation of VAST. Implementation outcomes will be measured.
| Study group | Role | What they receive |
|---|---|---|
| VAST | Other | Sites that implement VAST Receives: Other: Videoconference Antimicrobial Stewardship Team |
What is being measured
The primary outcome is the main question the study is designed to answer.
Days of Antibiotic Therapy (DOT) / 1000 Bed Days of Care (DOC)
Days of antibiotic therapy per 1000 days of care (DOT/1000 DOC), measures the overall rate of antibiotic use and is a common metric that accounts for dose adjustments, including for people who receive dialysis. Administration of any dose of an antimicrobial on a given day represents a single DOT for that agent, regardless of the number of times the doses are administered or the dose strength.
Measured: 2.25 years
Secondary outcomes (2)
Antibiotic Starts
The investigators will measure the rate of antibiotic starts (new prescriptions), calculated as the number of starts per 1000 DOC.
Measured: 2.25 years
Rate of Broad-spectrum Antibiotics
The investigators will specifically examine the rate of broad-spectrum antibiotics, defining broad-spectrum agents as those with an Antibiotic Spectrum Index (ASI) score of 8. This scale ranges from 1 to 13; the ASIs for penicillin, doxycycline, ciprofloxacin, and ertapenem are 2, 5, 8 and 9, respectively.
Measured: 2.25 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2026
- Study start24 Nov 2025
- Primary completion30 Sep 2030 (estimated)
- Study completion30 Sep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Common InfectionsStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The Videoconference Antimicrobial Stewardship Teams (VASTs) will be implemented in rural VA Medical Centers, as a type II hybrid implementation effectiveness trial through a quality improvement framework. VASTs will connect rural Veterans Affairs Medical Centers (VAMCs) with geographically distant infectious disease (ID) specialists via videoconferences to provide case-based stewardship. VASTs involve regularly scheduled videoconference sessions in which rural clinicians collaborate with off-site ID consultants to review patients either being considered for or currently receiving antimicrobial therapy.
- Masking
- None (open label)
- Enrolment
- 6 participants (estimated)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Charlesnika Tyon Evans, PhD MPH BS, Principal investigator, Edward Hines Jr. VA Hospital, Hines, IL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07877662
- Sponsor's protocol ID
- QUX 26-008
- Other IDs
- QUE 25-023, 1I50HX004140
- Acronym
- QUERI VAST
- Status last verified
- Sep 2026
- First submitted
- 25 Sep 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implement and Assess the Impact of a Multidisciplinary Videoconference Antimicrobial Stewardship Team (VAST) in Rural VAMCs Using Telehealth on Antimicrobial Prescribing (QUE 25-023)
- ClinicalTrials.gov ID
- NCT07877662
- Acronym / sponsor ID
- QUERI VAST / QUX 26-008
- Keywords
- Antimicrobial stewardship, Telemedicine, Rural health
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 6 participants (estimated)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Study start
- 24 Nov 2025 (actual)
- Primary completion
- 30 Sep 2030 (estimated)
- Study completion
- 30 Sep 2030 (estimated)
- First posted
- 16 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Antimicrobial-resistant and healthcare-associated pathogens are a global health threat. The goals of antimicrobial stewardship are to minimize unnecessary and inappropriate antimicrobial use as a means to combat antimicrobial resistance. The interdisciplinary Videoconference Antimicrobial Stewardship Team (VAST) was initially developed and tested as a telehealth teleconferencing training and mentoring program in 2 rural pilot sites, then was extended to 9 rural sites, using telehealth to connect clinicians at a rural VAMC to a geographically distant infectious disease expert. Qualitative interviews showed that participants valued VAST and it improved patient care. This project will expand the VAST to other VAMCs and assess the VASTs' impact on antimicrobial prescribing. This work will directly increase access to antimicrobial stewardship consultation at rural VA facilities, which are often underserved by infectious disease expertise.
Detailed description
Background: Antimicrobial resistance (AMR) is a current pandemic. Access to ID physicians and pharmacists in VHA is limited and many VHA healthcare systems do not have an ID specialist. This gap in expertise is detrimental, as the presence of ID trained physicians and pharmacists in acute care is associated with improved antimicrobial utilization. Telehealth can facilitate antimicrobial stewardship in VA facilities underserved by ID expertise. The interdisciplinary Videoconference Antimicrobial Stewardship Team (VAST)consists of weekly meetings between an interdisciplinary team at a rural VAMC with an off-site ID trained physician and/or pharmacist who meet by videoconference. At each session, participants discuss patients receiving antibiotics or who may potentially receive antibiotics. Team members enter the VAST's recommendations into the electronic medical record (EMR) at the rural VAMC. The ID physicians capture their clinical effort by completing interfacility consults placed through the EMR. The aims of this hybrid effectiveness trial are to assess the implementation of VAST and antibiotic utilization outcomes.
Aim 1: Implement and evaluate the implementation of VAST, using an implementation playbook with external facilitation and tailoring. VAST will be implemented over 15 months, plus sustainability follow-up in 6 rural VAMCs using key implementation strategies of external facilitation provided by CARRIAGE, tailoring and adaptation of VAST, and use of an implementation playbook. Process maps (which informed the playbook) from the previous VAST expansion captured VAST experiences at each site and illuminated successful implementation processes, showing that tailoring and adapting the VAST program based on site-specific needs, individual clinical processes, and patient care needs was crucial to its success and sustainability. The playbook details the general process for setting up an e-consult VAST clinic and scheduling and conducting VAST sessions. Site-specific tailoring, adaptation, and facilitation of VAST will occur based on playbook information. CARRIAGE members will hold initial facilitation calls weekly with VASTs, with ad hoc support available as well. CARRIAGE will facilitate an initial kick off meeting via Teams for each VAST to encourage team building and expectations for the ensuing sessions.
Aim 2: Assess the impact of VAST on antimicrobial use and the care of Veterans with suspected and confirmed infections. Using a quasi-experimental design, the investigators will assess outcomes for new rural sites implementing VAST and for the current rural sites currently using VAST to assess sustainability. For each site, the investigators will calculate these statistics monthly for the 12 months prior to and 15 months following the first VAST session (allowing for a 3-month wash-in period), and up to 24 months to assess sustainability. The investigators will include a control group of rural sites not utilizing VAST (matched). Antibiotic use metrics including rates of total and broad-spectrum anti-biotic use, antibiotic starts, and length of antibiotic therapy will be evaluated. The primary outcome is days of antibiotic therapy per 1000 days of care (DOT/1000 DOC) to measure the overall rate of antibiotic use; key secondary outcomes include rate of broad-spectrum antibiotics, defined as agents with an Antibiotic Spectrum Index score of ≥ 8;72 rate of antibiotic starts, calculated as the number of new starts per 1000 DOC; and length of antibiotic therapy in days. Other outcomes may be evaluated including management of resistant infections including treatment selection. The investigators will use VA CDW/Millennium to obtain antimicrobial prescribing, diagnosis, comorbidity, microbiologic, laboratory, and demographic data.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The Videoconference Antimicrobial Stewardship Teams (VASTs) will be implemented in rural VA Medical Centers, as a type II hybrid implementation effectiveness trial through a quality improvement framework. VASTs will connect rural Veterans Affairs Medical Centers (VAMCs) with geographically distant infectious disease (ID) specialists via videoconferences to provide case-based stewardship. VASTs involve regularly scheduled videoconference sessions in which rural clinicians collaborate with off-site ID consultants to review patients either being considered for or currently receiving antimicrobial therapy.
| Arm | Type | Receives |
|---|---|---|
| VAST | Other | Other: Videoconference Antimicrobial Stewardship TeamSites that implement VAST |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- -VA medical centers without local ID expertise that pair with an ID-expert from another VA medical center
Key exclusion criteria (1 listed)
- -none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Videoconference Antimicrobial Stewardship TeamAlso: VASTImplementation of VAST in hybrid effectiveness trial. Sites that implement VAST will have outcomes measured before and after implementation of VAST. Implementation outcomes will be measured. | Other | VAST |
Primary outcome
Days of Antibiotic Therapy (DOT) / 1000 Bed Days of Care (DOC)
Time frame: 2.25 years
Days of antibiotic therapy per 1000 days of care (DOT/1000 DOC), measures the overall rate of antibiotic use and is a common metric that accounts for dose adjustments, including for people who receive dialysis. Administration of any dose of an antimicrobial on a given day represents a single DOT for that agent, regardless of the number of times the doses are administered or the dose strength.
2 secondary outcomes
Antibiotic Starts
Time frame: 2.25 years
Rate of Broad-spectrum Antibiotics
Time frame: 2.25 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Common Infections
RecruitingPhase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency
Recruiting
Probiotic Trial for URTI Prevention in Healthy Adults
Upper Respiratory Tract Infections
Not yet recruiting
Enhanced Telemedicine in Primary Care for Acute Respiratory Tract Infections Study
Acute Respiratory Tract Infection, Ear Infection
RecruitingPhase 2
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative
Not yet recruitingObservational study
Post-market Clinical Follow-up Study of an Isotonic Saline Solution for the Relief of Nasal Congestion in Infants and Toddlers
Nasal Congestion, Common Cold
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Charlesnika Tyon Evans, PhD MPH BS principal investigator
Edward Hines Jr. VA Hospital, Hines, IL
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Videoconference Antimicrobial Stewardship Team in people with Common Infections and Urinary Tract Infections, run by VA Office of Research and Development at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Days of Antibiotic Therapy (DOT) / 1000 Bed Days of Care (DOC) (time frame: 2.25 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026; AzTrials last refreshed its copy on 7 Nov 2026.